Please try another search
For the three months ended 31 March 2022, Entasis Therapeutics Holdings Inc revenues was not reported. Net loss increased 43% to $15.3M. Higher net loss reflects General and administrative - Balancing increase of 61% to $4.6M (expense), Research and development - Balancing va increase of 19% to $10.6M (expense), Grant income decrease of 66% to $672K (income).
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | ||||
Operating Income | -15.93 | -12.74 | -13.6 | -13.3 |
Net Income | -15.26 | -12.02 | -12.39 | -12.03 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Total Assets | 44.09 | 40.92 | 50.77 | 63.56 |
Total Liabilities | 27.44 | 9.71 | 9.53 | 10.51 |
Total Equity | 16.65 | 31.21 | 41.23 | 53.06 |
Period Ending: | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 |
---|---|---|---|---|
Period Length: | 3 Months | 0 Months | 9 Months | 6 Months |
Cash From Operating Activities | -13.75 | -42.97 | -30.68 | -18.58 |
Cash From Investing Activities | -0.01 | -0.07 | -0.07 | -0.03 |
Cash From Financing Activities | 15 | 22.1 | 21.63 | 21.77 |
Net Change in Cash | 1.24 | -20.94 | -9.12 | 3.16 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review